Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Venetoclax, and Inotuzumab Ozogamicin in R/R Ph-ALL
NCT06087419Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tucidinostat in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT06087419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087419.